Vertex (VRTX), BioMarin (BMRN), Intercept (ICPT), Others Highlighted as Targets at BMO Following PFE/MDVN

Amid Pfizer's (NYSE: PFE) deal to acquire Medivation (NASDAQ: MDVN) for $14 billion, BMO Capital analyst Do Kim sees increased appeal for the remaining mid-cap biotech companies.

Kim issued a list of potential combination candidates in their coverage, using a 3-4x multiple on their peak revenue estimates, including: Vertex Pharma (NASDAQ: VRTX) and Ionis Pharma (NASDAQ: IONS) (covered by Kim group) and Alexion Pharma (NASDAQ: ALXN), AveXis (NASDAQ: AVXS), BioMarin (NASDAQ: BMRN), Intercept Pharma (NASDAQ: ICPT), and Neurocrine Biosciences (NASDAQ: NBIX) (covered by Ian Somaiya).

"We believe these companies could potentially command a higher multiple given the limited number of late-stage clinical and commercial biotechs," he said.

Using the 3-4x peak revenue multiple, the firm's chart shows AveXis (NASDAQ: AVXS), Intercept Pharma (NASDAQ: ICPT), and Neurocrine Biosciences (NASDAQ: NBIX) have the most potential upside in a deal.

You May Also Be Interested In

• This biotech stock could be the next M&A target after AbbVie's $8.7B deal for Cerevel
• Kia Motors (000270:KS) (KIMTF) PT Raised to KRW130,000 at JPMorgan
• Sumitomo Realty & Development Co Ltd (8830:JP) PT Raised to JPY4,000 at JPMorgan